Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
Despite concerns about potential competition from recently approved and available European biosimilars to Humira, AbbVie was able to stave off some of the losses expected during Q2 2019.
The EMA recommended approving Vitrakvi to tackle tumors with a specific genetic mutation regardless of where the disease started.
GW Pharmaceuticals’ marijuana-based treatment Epidyolex won a positive recommendation for marketing approval from a European Medicines Agency (EMA) panel for use as an additional treatment for two types of seizures.
AstraZeneca Plc raised the company’s product sales forecast for 2019 after second-quarter results beat analysts’ expectations, thanks to strong sales from cancer medicines and emerging markets, especially China.
Freenome snagged $160 million in Series B financing to support the development of the company’s early cancer detection blood test.
Biogen Inc. reported better-than-expected second quarter 2019 profit and raised the company’s full-year earnings forecast, driven by higher sales of the top-selling multiple sclerosis drug Tecfidera and lower taxes.
GlaxoSmithKline Plc’s cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said.
White House scraps proposal to lower U.S. drug prices
Analysts, Cigna, Consumers, CVS Health, Department of Health and Human Services (HHS), Health Insurance, Health Insurers, McKesson, Medicare, Prescription Drug Costs, Retail Pharmacies, Shares, Therapeutics, Trump Administration, UnitedHealth Group, Walgreens Boots Alliance, White HouseThe Trump administration scrapped a proposal for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients.
GlaxoSmithKline Plc’s two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial.
